Rollins Financial Advisors LLC Raises Stock Holdings in Eli Lilly and Company $LLY

Rollins Financial Advisors LLC boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 90.5% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,105 shares of the company’s stock after acquiring an additional 1,475 shares during the period. Rollins Financial Advisors LLC’s holdings in Eli Lilly and Company were worth $3,724,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Golden Reserve Retirement LLC increased its stake in shares of Eli Lilly and Company by 264.9% in the second quarter. Golden Reserve Retirement LLC now owns 2,423 shares of the company’s stock worth $2,906,000 after purchasing an additional 1,759 shares in the last quarter. New Paradigm Capital Management LLC purchased a new position in shares of Eli Lilly and Company during the 2nd quarter valued at $5,277,000. Investment Research Partners LLC lifted its stake in shares of Eli Lilly and Company by 11.7% during the 2nd quarter. Investment Research Partners LLC now owns 1,847 shares of the company’s stock valued at $2,215,000 after buying an additional 194 shares in the last quarter. Steinberganna Wealth Management boosted its holdings in Eli Lilly and Company by 2.2% in the 2nd quarter. Steinberganna Wealth Management now owns 959 shares of the company’s stock worth $1,150,000 after buying an additional 21 shares during the period. Finally, 71 West Capital Partners boosted its holdings in Eli Lilly and Company by 49.4% in the 2nd quarter. 71 West Capital Partners now owns 5,922 shares of the company’s stock worth $7,103,000 after buying an additional 1,959 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares in the company, valued at $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $1,184.44 on Tuesday. The firm has a market capitalization of $1.11 trillion, a price-to-earnings ratio of 39.75, a PEG ratio of 1.39 and a beta of 0.51. Eli Lilly and Company has a 1 year low of $685.15 and a 1 year high of $1,249.45. The business has a 50 day simple moving average of $1,171.52 and a 200-day simple moving average of $1,053.72. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating the consensus estimate of $6.40 by $1.98. The company had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm’s revenue was up 47.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities analysts forecast that Eli Lilly and Company will post 36.35 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is currently 23.22%.

Analyst Ratings Changes

LLY has been the topic of several recent analyst reports. The Goldman Sachs Group reissued a “buy” rating and set a $1,283.00 target price on shares of Eli Lilly and Company in a research note on Friday, May 22nd. BMO Capital Markets restated an “outperform” rating and issued a $1,400.00 price target on shares of Eli Lilly and Company in a research note on Thursday, August 6th. UBS Group set a $1,376.00 price objective on shares of Eli Lilly and Company in a report on Friday, August 7th. Rothschild & Co Redburn lifted their price objective on shares of Eli Lilly and Company from $880.00 to $900.00 in a research report on Thursday, May 7th. Finally, Citigroup boosted their target price on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,292.18.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Retatrutide results support higher guidance. Favorable trial results for retatrutide, Lilly’s next-generation obesity and diabetes candidate, reportedly prompted the company to lift its guidance. The update strengthens expectations that Lilly can extend its GLP-1 growth beyond Mounjaro and Zepbound. Eli Lilly Lifts Guidance on Retatrutide Trial Wins
• Positive Sentiment: New OmniAb collaboration expands Lilly’s discovery pipeline. Lilly signed a global collaboration and licensing agreement with OmniAb for an ion-channel drug-discovery program. The deal, which could provide OmniAb with up to $370 million in milestones, gives Lilly access to additional technology and potential future medicines while reinforcing its investment in pipeline development. OmniAb Announces Global Collaboration and License Agreement
• Positive Sentiment: Recent growth catalysts remain intact. Commentary highlights Lilly’s robust second-quarter performance, approximately 48% year-over-year revenue growth, UK regulatory approval, a Medicare access program and continuing GLP-1 demand. Analysts also point to strong momentum and a broad pipeline as reasons for long-term optimism. Eli Lilly’s Growth Story Keeps Adding Chapters
• Neutral Sentiment: Valuation remains debated. A discounted-cash-flow analysis suggests potential upside, but Lilly’s five-year total return of more than 360% and elevated trading multiples mean substantial future growth is already reflected in the stock. Can Eli Lilly Stay Undervalued If Growth Keeps Delivering?
• Negative Sentiment: Competition and pricing risks remain. Analysts view strong GLP-1 momentum favorably but caution that Lilly’s valuation is demanding and competition, pricing pressure and future patent headwinds could limit additional upside. LLY Up After Robust Q2 Results

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.